Bimekizumab gets PIM designation from MHRA for hidradenitis

5 June 2023

Belgium’s largest pharma company UCB (Euronext: UCB) today revealed that its developmental treatment for adults with hidradenitis suppurativa (HS) has been granted Promising Innovative Medicine (PIM) designation in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA).

Claire Brading, managing director, UCB UK said: “Hidradenitis suppurativa is a debilitating condition and we are delighted that the MHRA has recognized the potential of bimekizumab for patients living with the chronic pain of this disease. This is testament to our commitment to supporting patients with skin conditions in the UK and harnessing innovative science to do so.”

The company pointed out that the granting of a PIM designation is an early indication that an investigational treatment may be an eligible candidate for Early Access to Medicines (EAMS), which can provide patients with life threatening or seriously debilitating conditions pre-approval access to medicines where there is a clear unmet medical need. PIM is granted to products that meet all three of the following criteria.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK